Pharmacopsychiatry 2010; 43(3): 81-85
DOI: 10.1055/s-0029-1242816
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia: Consistency Across World Geographies and Study Designs

D. Novick1 , H. Ascher-Svanum2 , B. Zhu3 , A. Brnabic4 , V. Stauffer3 , X. Peng3 , J. Karagianis5 , E. Perrin6
  • 1European Outcomes Research, Eli Lilly and Co, Surrey, UK
  • 2Eli Lilly and Company, Indianapolis, Indiana, USA
  • 3Lilly USA, LLC, Indianapolis, Indiana, USA
  • 4Eli Lilly Australia Pty Ltd, Macquarie Park, Australia
  • 5Eli Lilly Canada, Toronto, Ontario, Canada, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada
  • 6Eli Lilly and Company, Suresnes, France
Further Information

Publication History

received 09.03.2009 revised 06.10.2009

accepted 06.10.2009

Publication Date:
16 December 2009 (eFirst)

Abstract

Introduction: The number needed to treat (NNT) for all-cause medication discontinuation in large, industry-sponsored, non-randomized, observational studies conducted across world geographies was compared with NNTs from CATIE, an 18-month, NIMH-sponsored, randomized study.

Methods: NNTs (with 95% confidence intervals) were calculated using data from 3 large Lilly-sponsored, non-randomized, observational studies (EU-SOHO, IC-SOHO, and US-SCAP, n=20 957). Group differences at medication initiation were adjusted by Cox regression modeling. These NNTs were compared with published NNTs for CATIE (phase 1).

Results: NNTs for olanzapine vs. risperidone and for olanzapine vs. quetiapine were similar across the observational studies and similar to those of CATIE. The NNTs for olanzapine vs. oral typical antipsychotics were similar across the observational studies but demonstrated a somewhat stronger effect size than the NNT reported for olanzapine vs. perphenazine in CATIE.

Discussion: NNTs for all-cause treatment discontinuation (a proxy measure of a medication's effectiveness from patients’ and clinicians’ perspectives) appear to be consistent across study designs (non-interventional, observational vs. RCT), study sponsorship (industry vs. independent), and across world geographies, suggesting that antipsychotics differ in this measure.

References

Correspondence

D. Novick

Eli Lilly and Company

Lilly Research Centre

Erl Wood Manor

Sunninghill Road

Windlesham

Surrey

GU20 6PH

UK

Phone: +44/(0)1276/483 832

Fax: +44/(0)1276/483 192

Email: Novick_diego@lilly.com